HUP0402080A2 - Kannabinoid receptor agonisták alkalmazása gastrooesophagealis reflux betegség kezelésére szolgáló gyógyszer előállítására - Google Patents

Kannabinoid receptor agonisták alkalmazása gastrooesophagealis reflux betegség kezelésére szolgáló gyógyszer előállítására

Info

Publication number
HUP0402080A2
HUP0402080A2 HU0402080A HUP0402080A HUP0402080A2 HU P0402080 A2 HUP0402080 A2 HU P0402080A2 HU 0402080 A HU0402080 A HU 0402080A HU P0402080 A HUP0402080 A HU P0402080A HU P0402080 A2 HUP0402080 A2 HU P0402080A2
Authority
HU
Hungary
Prior art keywords
treatment
receptor agonists
cannabionid
medicament
preparation
Prior art date
Application number
HU0402080A
Other languages
English (en)
Inventor
Anders Lehmann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HUP0402080A2 publication Critical patent/HUP0402080A2/hu
Publication of HUP0402080A3 publication Critical patent/HUP0402080A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)

Abstract

A találmány tárgya cannabinoid receptor agonisták vagygyógyszerészetileg elfogadható sóik vagy optikai izomereiknekalkalmazása a nyelőcső alsó záróizma átmeneti ellazulásainakgátlására, az átmeneti ellazulások következtében fellépő reflux,öklendezés, tüdőbetegség fejlődésbeli elmaradás, asztma, krónikusgégegyulladás megelőzésére vagy kezelésére szolgáló gyógyszerelőállítására. A kannabionid receptor agonista lehet például egyejkozanoid és egy amino-alkil-indol. Ó
HU0402080A 2001-11-23 2002-11-20 Use of cannabionid receptor agonists for the preparation of a medicament for treatment of gastroesophageal reflux disease HUP0402080A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103936 2001-11-23
PCT/SE2002/002108 WO2003043619A1 (en) 2001-11-23 2002-11-20 New use for the treatment of gastroesophageal reflux disease

Publications (2)

Publication Number Publication Date
HUP0402080A2 true HUP0402080A2 (hu) 2005-02-28
HUP0402080A3 HUP0402080A3 (en) 2008-03-28

Family

ID=20286096

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402080A HUP0402080A3 (en) 2001-11-23 2002-11-20 Use of cannabionid receptor agonists for the preparation of a medicament for treatment of gastroesophageal reflux disease

Country Status (20)

Country Link
US (1) US7358245B2 (hu)
EP (1) EP1453497A1 (hu)
JP (1) JP2005511632A (hu)
KR (1) KR20050044582A (hu)
CN (1) CN1610542A (hu)
AR (1) AR037299A1 (hu)
AU (1) AU2002353700A1 (hu)
BR (1) BR0214319A (hu)
CA (1) CA2466916A1 (hu)
HU (1) HUP0402080A3 (hu)
IL (1) IL161748A0 (hu)
IS (1) IS7272A (hu)
MX (1) MXPA04004774A (hu)
NO (1) NO20042613L (hu)
NZ (1) NZ532844A (hu)
PL (1) PL369402A1 (hu)
RU (1) RU2280443C2 (hu)
TW (1) TW200407110A (hu)
WO (1) WO2003043619A1 (hu)
ZA (1) ZA200403785B (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005039550A2 (en) * 2003-10-24 2005-05-06 Solvay Pharmaceuticals Gmbh Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
SE0303490D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use V
JP2008517976A (ja) 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
CN101132781A (zh) * 2004-12-09 2008-02-27 茵西斯医疗公司 在室温下稳定的屈大麻酚剂型
US20080112895A1 (en) * 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2009020666A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
EP2205240A1 (en) 2007-10-02 2010-07-14 Ariel-University Research And Development Company, Ltd. Endocannabinoids for enhancing growth and development in infants
US20090208588A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown GERD carbohydrate compositions
CN103588672A (zh) * 2013-10-28 2014-02-19 史克勇 一种治疗癌性疼痛的药物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
CA2340445A1 (en) 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
AU776414B2 (en) 1998-05-29 2004-09-09 Neurosciences Research Foundation, Inc. Control of pain with endogenous cannabinoids
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
IL132661A (en) 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
SE9904507D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
US6645987B2 (en) * 2000-06-15 2003-11-11 Schering Corporation Nor-seco himbacine derivatives useful as thrombin receptor antagonists
AUPR118000A0 (en) * 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
US20020077322A1 (en) 2000-12-15 2002-06-20 Ayoub George S. Protection of neurons against glutamate-induced damage in glaucoma and other conditions

Also Published As

Publication number Publication date
JP2005511632A (ja) 2005-04-28
AU2002353700A1 (en) 2003-06-10
MXPA04004774A (es) 2004-07-30
WO2003043619A8 (en) 2005-03-17
HUP0402080A3 (en) 2008-03-28
EP1453497A1 (en) 2004-09-08
TW200407110A (en) 2004-05-16
CN1610542A (zh) 2005-04-27
KR20050044582A (ko) 2005-05-12
RU2280443C2 (ru) 2006-07-27
RU2004114843A (ru) 2005-05-27
BR0214319A (pt) 2004-11-03
WO2003043619A1 (en) 2003-05-30
IL161748A0 (en) 2005-11-20
NO20042613L (no) 2004-08-13
ZA200403785B (en) 2005-05-19
AR037299A1 (es) 2004-11-03
PL369402A1 (en) 2005-04-18
US20040266861A1 (en) 2004-12-30
US7358245B2 (en) 2008-04-15
CA2466916A1 (en) 2003-05-30
NZ532844A (en) 2005-12-23
IS7272A (is) 2004-05-19

Similar Documents

Publication Publication Date Title
BRPI0409910A (pt) métodos para o tratamento de doenças relacionadas com interleucina-6
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
DE50212546D1 (de) Orale darreichungsformen für propiverin oder seinen pharmazeutisch annehmbaren salzen mit verlängerter wirkstofffreisetzung
BRPI0013478B8 (pt) medicamento compreendendo inibidor pde e uso de roflumilast
HUP0101694A1 (hu) Gyulladásos bélbetegségek kezelésére vagy megelőzésére szolgáló, hatóanyagként IL-6 antagonistát tartalmazó készítmény
LTC1562603I2 (lt) Nauji vaistai, skirti lėtinių obstrukcinių plaučių ligų gydymui
ATE361077T1 (de) Indanylderivate zur behandlung von atemwegserkrankungen
HUP0301452A2 (hu) Fotokemoterápiás szert és mukoadhéziós szert tartalmazó gyógyszerkészítmény és alkalmazása
EA200701357A1 (ru) Композиции и способы применения модулятора рецептора 5ht
HUP0402080A2 (hu) Kannabinoid receptor agonisták alkalmazása gastrooesophagealis reflux betegség kezelésére szolgáló gyógyszer előállítására
ITTO20040621A1 (it) Immunogeno sintetico per la terapia e profilassi dell'abuso di droghe e sostanze psicoattive
EA200702282A1 (ru) Комбинация феррохина и производного артемизинина для лечения малярии
CY1106845T1 (el) Χρηση της φλουμαζενιλης για την παρασκευη ενος φαρμακου για την αγωγη της εξαρτησεως απο την κοκαϊνη
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
HUP0203844A2 (hu) Növekedési hormon kibocsátó tulajdonságú vegyület, ezt tartalmazó gyógyszerkészítmény és alkalmazása
HUP0401805A2 (hu) Pulmonális betegségek kezelésére szolgáló vegyületek
NO20070522L (no) Oral vedvarende frigivelsesformulering av tedisamil med gastriske bibeholdelsesegenskaper
HUP0400222A2 (hu) PDE-4 inhibitort és H1 receptor antagonistát tartalmazó kombináció és ennek alkalmazása tüdőbetegségek kezelésére alkalmas gyógyszerkészítmény előállítására
ATE275405T1 (de) Sucralfat enthaltendes arzneimittel zur behandlung von zervikale erosion
EE200300328A (et) IL-18 inhibiitorite kasutamine südamehaiguse raviks ja/või ennetamiseks
HUP0402358A2 (hu) Szelektív dopamin D4 receptor agonisták alkalmazása szexuális diszfunkciók kezelésére alkalmas gyógyszerkészítmény előállítására
ATE325115T1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
ITRM20030596A1 (it) Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
DE602005017629D1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
HUP0401599A2 (hu) Elnyújtott kibocsátású új orális adagolási forma

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees